Will GHK-Cu become legal? The PCAC review
The FDA’s Pharmacy Compounding Advisory Committee reviews GHK-Cu on before end of Feb 2027. It is currently not FDA-approved and not legal to compound; the vote is the first formal step toward potential legal compounding.
A committee “yes” is a recommendation, not legalization. The path has two stages: first the PCAC vote, then formal FDA rulemaking. Each peptide effectively turns on both — which is why a favorable vote still doesn’t mean you can fill a prescription the next day.
What happens on before end of Feb 2027
The FDA’s Pharmacy Compounding Advisory Committee will hear evidence and vote on whether GHK-Cu should be added to the 503A list for skin aging. A “yes” is a recommendation only; the FDA would then need to issue a final rule before any pharmacy could legally compound it. Realistic patient access, if it happens at all, is late 2026 to early 2027.
Will GHK-Cu become legal in 2026?+
Is “research-grade” GHK-Cu the same as a medicine?+
Primary sources: FDA 503A interim list (Apr 2026 update) · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. GHK-Cu is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.